Intratumoral implantation of murine cells modified to produce retroviral vectors containing the herpes simplex virus-thymidine kinase (HSV-TK) gene induces regression of experimental brain tumors in rodents after ganciclovir (GCV) administration. We evaluated this approach in 15 patients with progressive growth of recurrent malignant brain tumors. Antitumor activity was detected in five of the smaller tumors (1.4 ± 0.5 ml). In situ hybridization for HSV-TK demonstrated survival of vector-producing cells (VPCs) at 7 days but indicated limited gene transfer to tumors, suggesting that indirect, “bystander,” mechanisms provide local antitumor activity in human tumors. However, the response of only very small tumors in which a high density of vector-producing cells had been placed suggests that techniques to improve delivery and distribution of the therapeutic gene will need to be developed if clinical utility is to be achieved with this approach.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Barba, D., Hardin, J., Ray, J. & Gage, F.H. Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729–735 (1993).
Culver, K.W. et al. In vivo gene transfer with retroviral vector-producing cells for treatment of experimental brain tumors. Science 256, 1550–1552 (1992).
Ezzeddine, Z.D. et al. Selective killing of glioma Cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 3, 608–614 (1991).
Caruso, M. et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA 90, 7024–7028 (1993).
Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276–5281 (1986).
Ram, Z., Culver, K.W., Walbridge, S., Blaese, R.M. & Oldfield, E.H. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83–88 (1993).
Mann, R., Mulligan, R.C. & Baltimore, D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153–159 (1983).
Short, M.P. et al. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line. J. Neurosci. Res. 27, 427–439 (1990).
Burger, P. & Scheithauer, B. Tumors of the central nervous system. in Atlas of Tumor Pathology, Third Series, Fascicle 10, p. 59 (Armed Forces Institute of Pathology, Washington, D. C., 1994).
Burger, P., Scheithauer, B. & Vogel, F. Surgical Pathology of the Nervous System and Its Coverings. (Churchill Livingstone, New York, 1991).
Bi, W.L., Parysek, L.M., Warnick, R. & Stambrook, P.J. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV Tk retroviral gene therapy. Hum. Gene Ther. 4, 725–731 (1993).
Ishii, H. et al. Mechanism of “bystander effect” killing in the herpes simplex thymidine kinase gene therapy model of cancer. Gene Ther. 4, 244–251 (1997).
Kato, K., Yoshida, J., Mizuno, M., Sugita, K. & Emi, N. Retroviral transfer of herpes simplex thymidine kinase into glioma Cells targeting of gancyclovir cytotoxic effect. Neurol. Med. Chir. (Tokyo) 34, 339–344 (1994).
Wu, J., et al. Bystander tumoricidal effect in the treatment of experimental brain tumors. Neurosurgery 35, 1094–1102 (1994).
Freeman, S.M., et al. The bystander effect: Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274–5283 (1993).
Denekamp, J. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Rad. 66, 181–196 (1993).
Ram, Z., et al. The effect on tumoral vascufature and growth of thymidine kinase-transduced, ganciclovir-treated 9L gliomas in rats. J. Neurosurg. 81, 256–260 (1994).
Barba, D., Hardin, J., Sadelain, M. & Gage, F.H. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91, 4348–4352 (1994).
Moolten, F.L. & Wells, J.M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297–300 (1990).
Lyons, R. et al. An improved vector encoding the herpes simplex virus thymidine kinase gene increases antitumor efficacy in vivo. Cancer Gene Ther. 2, 273–280 (1995).
Boviatsis, E. et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 15, 5745–5751 (1994).
Perez-Cruet, M., et al. Adenovirus-mediated gene therapy of experimental gliomas. J. Neurosci. Res. 39, 506–511 (1994).
Chen, S.H., Shine, H.D., Goodman, J.C., Grossman, R.G. & Woo, S.L. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. USA 91, 3054–3057 (1994).
Oldfield, E.H., Ram, Z., Culver, K.W., DeVroom, H.L. & Blaese, R.M. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4, 39–69 (1993).
Haapala, D.K., Robey, W.G., Oroszlan, S.D. & Tsai, W.P. Isolation from cats of an endogenous type C virus with a novel envelope glycoprotein. J. Virol. 53, 827–833 (1985).
Cairncross, G., et al. Chemotherapy for anaplastic oligodendroglioma. J. Clin. Oncol. 12, 2013–2021 (1994).
Macdonald, D., Cascino, T., Schold, S. & Cairncross, J. Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277–1280 (1990).
Pantaleo, G. et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355–358 (1993).
Hsu, S.M., Raine, L. & Fanger, H. A comparative study of the PAP method and avidin-biotin-complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol. 75, 734–738 (1981).
About this article
Cite this article
Ram, Z., Culver, K., Oshiro, E. et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3, 1354–1361 (1997). https://doi.org/10.1038/nm1297-1354
Neurosurgical Review (2021)
Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
Neuro-Oncology Advances (2020)
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats
Cancer Gene Therapy (2020)